Novo Nordisk A/S (NVO)
41.65
+1.00
(+2.46%)
USD |
NYSE |
Nov 13, 16:00
41.48
-0.17
(-0.41%)
After-Hours: 18:16
Novo Nordisk Enterprise Value : 149.40B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 149.40B |
| November 11, 2026 | 150.87B |
| November 10, 2026 | 149.57B |
| November 09, 2026 | 151.84B |
| November 06, 2026 | 148.26B |
| November 05, 2026 | 148.23B |
| November 04, 2026 | 154.52B |
| November 03, 2026 | 147.86B |
| November 02, 2026 | 148.73B |
| October 30, 2026 | 147.23B |
| October 29, 2026 | 144.35B |
| October 28, 2026 | 141.50B |
| October 27, 2026 | 142.78B |
| October 26, 2026 | 144.31B |
| October 23, 2026 | 144.05B |
| October 22, 2026 | 145.32B |
| October 21, 2026 | 144.08B |
| October 20, 2026 | 145.05B |
| October 19, 2026 | 141.94B |
| October 16, 2026 | 143.31B |
| October 15, 2026 | 144.62B |
| October 14, 2026 | 140.94B |
| October 13, 2026 | 140.73B |
| October 12, 2026 | 142.47B |
| October 09, 2026 | 142.68B |
| Date | Value |
|---|---|
| October 08, 2026 | 141.14B |
| October 07, 2026 | 141.40B |
| October 06, 2026 | 138.96B |
| October 05, 2026 | 138.99B |
| October 02, 2026 | 138.26B |
| October 01, 2026 | 138.53B |
| September 30, 2026 | 140.23B |
| September 29, 2026 | 142.73B |
| September 28, 2026 | 144.07B |
| September 25, 2026 | 144.37B |
| September 24, 2026 | 143.77B |
| September 23, 2026 | 142.26B |
| September 22, 2026 | 146.38B |
| September 21, 2026 | 147.72B |
| September 18, 2026 | 159.23B |
| September 17, 2026 | 159.06B |
| September 16, 2026 | 154.11B |
| September 15, 2026 | 156.85B |
| September 14, 2026 | 159.93B |
| September 11, 2026 | 158.66B |
| September 10, 2026 | 161.80B |
| September 09, 2026 | 163.64B |
| September 08, 2026 | 165.65B |
| September 04, 2026 | 170.47B |
| September 03, 2026 | 173.52B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 598.18B |
| GSK Plc | 128.54B |
| Johnson & Johnson | 709.89B |
| Eli Lilly & Co. | 1.388T |
| Merck & Co., Inc. | 406.57B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.576B |
| Revenue (Quarterly) | 12.19B |
| Total Expenses (Quarterly) | 9.612B |
| EPS Diluted (Quarterly) | 0.5825 |
| Gross Profit Margin (Quarterly) | 82.10% |
| Profit Margin (Quarterly) | 21.14% |
| Earnings Yield | 9.53% |
| Operating Earnings Yield | 13.57% |
| Normalized Earnings Yield | 10.56 |